The requirement to stratify cancer patients for receptor-targeted therapy is well recognized for PSMA which is widely expressed in normal human tissues, including bladder, kidney, testis, ovary, fallopian tube, breast, adrenal gland, liver, esophagus, stomach, small intestine, colon, and brain, as well as in hyperplastic prostate, Barrett's esophagus, and tumors of the prostate, bladder, kidney, testis, esophagus, stomach, small intestine, colon, adrenal gland, and lung 33. The gene discussed is FOLH1; the disease is prostate neoplasm.